DE69123123D1 - Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen - Google Patents

Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen

Info

Publication number
DE69123123D1
DE69123123D1 DE69123123T DE69123123T DE69123123D1 DE 69123123 D1 DE69123123 D1 DE 69123123D1 DE 69123123 T DE69123123 T DE 69123123T DE 69123123 T DE69123123 T DE 69123123T DE 69123123 D1 DE69123123 D1 DE 69123123D1
Authority
DE
Germany
Prior art keywords
cyclopentyloxycarbonylamino
methylbenzenesulfonamide
methoxybenzoyl
indol
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69123123T
Other languages
English (en)
Other versions
DE69123123T2 (de
Inventor
Martin Paul Edwards
John David Sherwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DE69123123D1 publication Critical patent/DE69123123D1/de
Publication of DE69123123T2 publication Critical patent/DE69123123T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69123123T 1990-12-12 1991-12-11 Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen Expired - Lifetime DE69123123T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909027018A GB9027018D0 (en) 1990-12-12 1990-12-12 Heterocyclic compounds

Publications (2)

Publication Number Publication Date
DE69123123D1 true DE69123123D1 (de) 1996-12-19
DE69123123T2 DE69123123T2 (de) 1997-03-06

Family

ID=10686919

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69123123T Expired - Lifetime DE69123123T2 (de) 1990-12-12 1991-12-11 Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen

Country Status (28)

Country Link
US (1) US5294636A (de)
EP (1) EP0490649B1 (de)
JP (1) JP2650807B2 (de)
KR (1) KR100194479B1 (de)
CN (2) CN1032469C (de)
AP (1) AP286A (de)
AT (1) ATE145199T1 (de)
AU (1) AU656344B2 (de)
CA (1) CA2056067C (de)
CZ (1) CZ288151B6 (de)
DE (1) DE69123123T2 (de)
DK (1) DK0490649T3 (de)
ES (1) ES2094797T3 (de)
FI (1) FI101296B (de)
GB (2) GB9027018D0 (de)
GR (1) GR3021605T3 (de)
HK (1) HK81497A (de)
HU (2) HU213109B (de)
IE (1) IE914316A1 (de)
IL (1) IL100090A (de)
MX (1) MX9102475A (de)
MY (1) MY108629A (de)
NZ (1) NZ240940A (de)
PH (1) PH30041A (de)
RU (1) RU2107682C1 (de)
SK (1) SK279018B6 (de)
TW (1) TW222264B (de)
ZA (1) ZA919772B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE113581T1 (de) * 1990-05-04 1994-11-15 Ciba Geigy Ag Substituierte indole.
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
IL111080A (en) * 1993-10-01 1999-08-17 Astra Ab Method for treating a finely divided powder medicament
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
EP1855651A4 (de) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen heterocyclischer amidderivate
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
CA2695008A1 (en) * 2007-07-30 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted indoles
TWI469965B (zh) * 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103396353B (zh) * 2013-08-23 2015-05-20 海南通用三洋药业有限公司 一种扎鲁司特无定型态及其制备方法
CA2936332A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
WO2018140858A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
WO2022243942A1 (en) 2021-05-19 2022-11-24 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives

Also Published As

Publication number Publication date
ATE145199T1 (de) 1996-11-15
EP0490649B1 (de) 1996-11-13
FI915825A0 (fi) 1991-12-11
IE914316A1 (en) 1992-06-17
CN1074411C (zh) 2001-11-07
GB2250743B (en) 1995-02-15
HU211125A9 (en) 1995-10-30
FI915825A (fi) 1992-06-13
KR920012031A (ko) 1992-07-25
HU913863D0 (en) 1992-02-28
GB2250743A (en) 1992-06-17
RU2107682C1 (ru) 1998-03-27
GB9027018D0 (en) 1991-01-30
HUT60717A (en) 1992-10-28
CA2056067A1 (en) 1992-06-13
AU656344B2 (en) 1995-02-02
DE69123123T2 (de) 1997-03-06
JP2650807B2 (ja) 1997-09-10
JPH04266872A (ja) 1992-09-22
HU213109B (en) 1997-02-28
MY108629A (en) 1996-10-31
CA2056067C (en) 2001-09-04
ZA919772B (en) 1992-09-30
DK0490649T3 (da) 1997-04-21
ES2094797T3 (es) 1997-02-01
IL100090A (en) 1996-09-12
CN1032469C (zh) 1996-08-07
US5294636A (en) 1994-03-15
PH30041A (en) 1996-11-08
AP9100341A0 (en) 1992-01-31
GR3021605T3 (en) 1997-02-28
FI101296B1 (fi) 1998-05-29
AU8899591A (en) 1992-06-18
CN1063100A (zh) 1992-07-29
KR100194479B1 (ko) 1999-06-15
IL100090A0 (en) 1992-08-18
CS375891A3 (en) 1992-06-17
CZ288151B6 (en) 2001-05-16
EP0490649A1 (de) 1992-06-17
HK81497A (en) 1997-06-27
NZ240940A (en) 1994-05-26
GB9126353D0 (en) 1992-02-12
MX9102475A (es) 1992-06-01
SK279018B6 (sk) 1998-05-06
FI101296B (fi) 1998-05-29
AP286A (en) 1993-09-26
CN1148491A (zh) 1997-04-30
TW222264B (de) 1994-04-11

Similar Documents

Publication Publication Date Title
DE69123123D1 (de) Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen
FI101193B1 (fi) Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalista muotoa sisältävän farmaseuttisen koostumuksen valmistamiseksi
DE69131813D1 (de) Amido-3-Pyrazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
DE69007069D1 (de) Kniescheibenprothese und Verfahren zu deren Herstellung.
DE69634806D1 (de) Substituierte heterocyclische Verbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE59609501D1 (de) Kristallmodifikation des CDCH, Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE122007000002I2 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
DE69006290D1 (de) N-Substituierte Benzyloxyiminderivate, Verfahren zu deren Herstellung und deren Verwendung.
IS1855B (is) (-) cis-6(S)-fenýl-5(R)-[4-(2-pýrrólidín-1-ýl-etoxý)fenýl]-5,6,7,8-tetrahýdrónaftalen-2-ól-D-tartrat, notkun, lyfjablanda og framleiðsla hennar
HUP9802630A3 (en) Chiral methyl phenyl oxazolidinones, process for their preparation, use thereof and pharmaceutical compositions containing them
DK0386452T3 (da) Diphenylheteroalkylderivater, fremgangsmåde til fremstilling heraf og lægemidler og kosmetika indeholdende disse
DE69124769D1 (de) Verfahren zur Herstellung von (1'R,3S)-3-(1'-hydroxy-ethyl)-Azetidin-2-on und deren Derivaten
IL98784A0 (en) Heterocyclyl sulfonamide derivatives,process for their preparation and pharmaceutical compositions containing them
ATE56956T1 (de) (s)-(-)-1-propyl-2',6'-pipecoloxylididhydrochloridmonohydrat, verfahren zu seiner herstellung und es enthaltendes pharmazeutisches praeparat.
MX9203505A (es) N-aril-n-(4-(1-alquilheterociclico)-piperidinil) amidas y composicines farmaceuticas y metodos que emplean dichos compuestos.
DE3777122D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69105369D1 (de) Pastenzusammensetzung und Verfahren zu deren Herstellung.
DE3868309D1 (de) Imidazol-derivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammenstellungen und deren anwendung als arzneimittel.
DE3767894D1 (de) 1,2-dithiol-3-thion-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
DE59108499D1 (de) Oligomerengemische von Triphendioxazinverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
DK1100775T3 (da) 2,5-Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til fremstilling deraf, anvendelse deraf og farmaceutiske præparater indeholdende disse
DE59009107D1 (de) 1-E3-(2-Hydroxy-3-alkylaminopropoxy)-2-thienyl]-3-phenyl-1-propanone und Verfahren zu deren Herstellung.
ATE148451T1 (de) Ng-monomethyl-l-arginin-hydrochlorid-derivate und verfahren zu deren herstellung
DK0654028T3 (da) 3- og 5-substituerede 1,2,3,4-oxatriazol-5-iminforbindelser og fremgangsmåde til fremstilling deraf, farmaceutisk præparat indeholdende disse forbindelser samt forbindelsernes anvendelse til fremstilling af lægemidler
DE69128845D1 (de) 4-[3-(4-Oxothiazoldinyl)]butynylamine, Verfahren zu deren Herstellung und ihre Verwendung als Medikament

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB